Pyridostigmine: using a cholinesterase inhibitor to activate the cholinergic anti-inflammatory pathway in patients with CRPS-1 - Pyridostigmine trial
- Conditions
- Patients with CRPS-1.
- Registration Number
- EUCTR2009-010758-36-NL
- Lead Sponsor
- VU University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
CRPS-1 patients (Veldman criteria).
Age > 18 jaar
Standard treatment does not solve the complaints adequately.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
kydney failure
other chronic pain syndromes
parkinson's disease
epilepsy
asthma
operations on the digestive tract in medical history
active malignancy
mental retardation
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Secondary Objective: A secondary objective is an evaluation of possible improvement of clinical well being of the patients treated with Pyridostigmine. <br>Side-effects of Pyridostigmine will be measured on a standardized scale. ;Primary end point(s): Improvement of functional status;Main Objective: The main objective of this trial is to evaluate the effect of Pyridostigmine (cholinesterase inhibitor) on inflammatory signs as pain, temperature, swelling and functional status of the extremity.<br><br>
- Secondary Outcome Measures
Name Time Method